In vivo, in the syngeneic model of AML treatment of mice transplanted with wildtype MLL-AF9+ LIC with the combination of NPS-2143 and cytarabine (ara-C) (Fig. 6e), considered standard of care, once the disease was established (Supplementary Fig. 20c), resulted in a significant reduction of leukocytes (Supplementary Fig. 20d) and a trend towards a reduction of MLL-AF9+ Gr1+ myeloid cells (Supplementary Fig. 20e) in PB compared to mice treated with ara-C alone. This evidence concerns the gene MLLT3 and acute myeloid leukemia.